VU-0152100: Difference between revisions

From WikiMD's Wellness Encyclopedia

Newer edit →
CSV import
 
CSV import
Line 1: Line 1:
{{Infobox drug
== VU-0152100 ==
| name = VU-0152100
| image = <!-- Image of the chemical structure -->
| width = 200px
| alt =
| caption = Chemical structure of VU-0152100
| IUPAC_name = <!-- IUPAC name -->
| CAS_number = <!-- CAS number -->
| PubChem = <!-- PubChem ID -->
| ChemSpiderID = <!-- ChemSpider ID -->
| UNII = <!-- UNII -->
| KEGG = <!-- KEGG ID -->
| ChEMBL = <!-- ChEMBL ID -->
| C= <!-- Number of carbon atoms -->
| H= <!-- Number of hydrogen atoms -->
| N= <!-- Number of nitrogen atoms -->
| O= <!-- Number of oxygen atoms -->
| molecular_weight = <!-- Molecular weight -->
}}


'''VU-0152100''' is a chemical compound that acts as a selective positive allosteric modulator of the [[metabotropic glutamate receptor]] subtype mGluR4. It is primarily used in scientific research to study the role of mGluR4 in the central nervous system and its potential therapeutic applications.
[[File:VU-0152100.svg|thumb|Chemical structure of VU-0152100]]
VU-0152100 is a chemical compound that acts as a selective antagonist for the [[M5 muscarinic receptor]]. It is used primarily in scientific research to study the role of the M5 receptor in various physiological processes.


==Mechanism of Action==
== Chemical Properties ==
VU-0152100 functions by binding to an allosteric site on the mGluR4 receptor, which is distinct from the orthosteric site where the endogenous ligand, [[glutamate]], binds. This binding enhances the receptor's response to glutamate, thereby modulating neurotransmission. The mGluR4 receptor is a G-protein coupled receptor (GPCR) that is involved in the regulation of neurotransmitter release in the brain.


==Pharmacological Effects==
VU-0152100 has the IUPAC name 3-((3-chlorophenyl)carbamoyl)-1-benzylpyridin-1-ium chloride. It is a small molecule with a molecular formula of C19H16Cl2N2O and a molecular weight of 359.25 g/mol. The compound is typically synthesized in a laboratory setting and is not found naturally.
The activation of mGluR4 by VU-0152100 has been shown to have several effects in preclinical models:


* '''Neuroprotection''': VU-0152100 has demonstrated neuroprotective effects in models of [[Parkinson's disease]], suggesting its potential as a therapeutic agent for neurodegenerative disorders.
== Mechanism of Action ==
* '''Analgesia''': Modulation of mGluR4 has been associated with analgesic effects, indicating a possible role in pain management.
* '''Anxiolytic Effects''': Studies have shown that VU-0152100 may reduce anxiety-like behaviors, which could be beneficial in treating anxiety disorders.


==Research Applications==
As an antagonist of the M5 muscarinic receptor, VU-0152100 binds to this receptor and inhibits its activity. The M5 receptor is one of the five subtypes of muscarinic receptors, which are part of the [[G protein-coupled receptor]] family. These receptors are activated by the neurotransmitter [[acetylcholine]]. The M5 receptor is less well understood than the other muscarinic receptors, but it is believed to play a role in modulating [[dopamine]] release in the brain.
VU-0152100 is used extensively in research to explore the therapeutic potential of mGluR4 modulation. It serves as a tool compound to:


* Investigate the role of mGluR4 in various neurological and psychiatric disorders.
== Research Applications ==
* Develop new therapeutic strategies targeting mGluR4 for conditions such as [[schizophrenia]], [[anxiety disorders]], and [[chronic pain]].


==Safety and Toxicology==
VU-0152100 is used in research to explore the function of the M5 receptor. Studies have suggested that the M5 receptor may be involved in the regulation of [[reward pathways]] and [[addiction]]. By using VU-0152100 to block the M5 receptor, researchers can investigate how this receptor influences these processes. Additionally, VU-0152100 has been used in studies examining the potential therapeutic applications of M5 receptor modulation in conditions such as [[schizophrenia]] and [[Parkinson's disease]].
As a research compound, VU-0152100 is not approved for clinical use in humans. Its safety profile is primarily characterized in animal studies, where it has shown a favorable safety margin. However, further studies are required to fully understand its toxicological properties.


==Also see==
== Related Pages ==
* [[Metabotropic glutamate receptor]]
* [[Allosteric modulator]]
* [[Neurotransmission]]
* [[Parkinson's disease]]
* [[G-protein coupled receptor]]


{{Receptor modulators}}
* [[Muscarinic acetylcholine receptor]]
{{Neuropharmacology}}
* [[G protein-coupled receptor]]
* [[Dopamine]]
* [[Neurotransmitter]]


[[Category:Pharmacology]]
[[Category:Muscarinic antagonists]]
[[Category:Neuroscience]]
[[Category:Research chemicals]]

Revision as of 11:57, 9 February 2025

VU-0152100

Chemical structure of VU-0152100

VU-0152100 is a chemical compound that acts as a selective antagonist for the M5 muscarinic receptor. It is used primarily in scientific research to study the role of the M5 receptor in various physiological processes.

Chemical Properties

VU-0152100 has the IUPAC name 3-((3-chlorophenyl)carbamoyl)-1-benzylpyridin-1-ium chloride. It is a small molecule with a molecular formula of C19H16Cl2N2O and a molecular weight of 359.25 g/mol. The compound is typically synthesized in a laboratory setting and is not found naturally.

Mechanism of Action

As an antagonist of the M5 muscarinic receptor, VU-0152100 binds to this receptor and inhibits its activity. The M5 receptor is one of the five subtypes of muscarinic receptors, which are part of the G protein-coupled receptor family. These receptors are activated by the neurotransmitter acetylcholine. The M5 receptor is less well understood than the other muscarinic receptors, but it is believed to play a role in modulating dopamine release in the brain.

Research Applications

VU-0152100 is used in research to explore the function of the M5 receptor. Studies have suggested that the M5 receptor may be involved in the regulation of reward pathways and addiction. By using VU-0152100 to block the M5 receptor, researchers can investigate how this receptor influences these processes. Additionally, VU-0152100 has been used in studies examining the potential therapeutic applications of M5 receptor modulation in conditions such as schizophrenia and Parkinson's disease.

Related Pages

Retrieved from "https://wikimd.com/index.php?title=VU-0152100&oldid=6199768"